<DOC>
	<DOCNO>NCT01659762</DOCNO>
	<brief_summary>In Phase I trial investigator intend show safety tolerability autologous MSC , expand use non-xenogeneic , human component platelet lysate expansion medium . Fresh , non cryopreserved , autologous MSCs deliver intravenously single bolus dose dose escalation phase I study . The investigator intend test whether product clinically safe adult ( 18-65 year old ) CD determine maximal deliverable dose . Secondary endpoint monitor effectiveness use CDAI endpoint .</brief_summary>
	<brief_title>A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal Crohn 's Disease .</brief_title>
	<detailed_description>EPIC MSC/IBD make autologous marrow-derived mesenchymal stromal cell ex vivo expand numerically approximately 14 day use pooled human Platelet Lysate ( phPL ) , harvest day infusion , wash suspend concentration 4 million cells/ml Plasmalyte A 0.5 % human serum albumin . This phase I dose-escalation , open label , non-randomized , non-placebo control , single group assignment study evaluate safety tolerability single intravenous infusion EPIC MSC2011-001 . EPIC EPIC MSC/IBD infuse intravenously administer one three dose level : ( Tier 1 ) 2 million cells/kg patient body weight ; ( Tier 2 ) 5 million cells/kg , ( Tier 3 ) 10 million cells/kg . This Phase I clinical trial enroll 16-20 subject moderate severe Crohn 's . The duration study patient 12 week . The investigator anticipate study complete within 2 year commencement . Primary objective : To describe compare safety tolerability single infusion fresh autologous bone marrow derive Mesenchymal stromal cell infused patient moderate severe Crohn 's disease . Secondary objective : Efficacy autologous bone marrow derive Mesenchymal stromal cell infusion patient moderate severe Crohn 's disease assess disease activity index , quality life index . Safety variable : Adverse event ( AEs ) , Laboratory parameter ( hematology , biochemistry , urinalysis ) , Vital sign .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion Criteria Men woman 1865 year age . Patient must CD least 3 month time initial diagnosis . The diagnosis CD must confirm endoscopic histological evidence . Patients must active Crohn 's disease define Crohns Disease Activity Index ( CDAI ) score &gt; 220 screen baseline . Patients need immediate surgery ( i.e . due obstruction , stricture , active abscess perforation ) . Subjects must refractory ( defined lack response least 3 month ) immunomodulators ( include 6mercaptopurine azathioprine methotrexate ) antiTNF therapy present point course disease . Lack response define failure reduce CDAI score least 70 point . The following medication allow : mesalamine prednisone ( stable dose least 2 week prior enrollment ) . Subjects anti TNF therapy require minimum 4 week washout period prior screen . Subjects nonsteroidal analgesic require minimum 2 week washout period prior screen If female childbearing age , patient must nonpregnant , nonbreastfeeding , use adequate contraception ; Patient willing participate study sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>